Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies
Accumulating evidence confirmed that many dysregulated signaling pathways and aberrant genetic alterations contribute to the oncogenesis and heterogeneity of lymphoid malignancies. Therapeutically targeting dysregulating signaling pathways and their hidden oncogenic biomarkers are becoming available...
Guardado en:
Autores principales: | Rui-Fang Sun, Qian-Qian Yu, Ken H. Young |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
KeAi Communications Co., Ltd.
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f5257862057e4693b762c1a2147473ce |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Hippo Signaling Pathway Dysregulation in Human Huntington’s Disease Brain and Neuronal Stem Cells
por: Kaly A. Mueller, et al.
Publicado: (2018) -
The evaluation and optimal use of rituximab in lymphoid malignancies
por: Smolewski P, et al.
Publicado: (2012) -
Analysis of Mutations and Dysregulated Pathways Unravels Carcinogenic Effect and Clinical Actionability of Mutational Processes
por: Zedong Jiang, et al.
Publicado: (2021) -
Endosomal phosphatidylserine is critical for the YAP signalling pathway in proliferating cells
por: Tatsuyuki Matsudaira, et al.
Publicado: (2017) -
Premature differentiation of nephron progenitor cell and dysregulation of gene pathways critical to kidney development in a model of preterm birth
por: Aleksandra Cwiek, et al.
Publicado: (2021)